Differential functions of TLE1 and TLE3 depending on a specific phosphorylation site

Area of Science:

• Molecular Biology
• Cancer Research
• Epigenetics

Background:

• Mammalian Transducin-like enhancer of split (TLE) proteins are transcriptional corepressors involved in diverse cellular processes.
• TLE proteins play roles in signal transduction pathways and have been implicated in cancer development.
• TLE3 has been proposed as a potential marker for enhanced chemosensitivity.

Purpose of the Study:

• To investigate the differential roles of TLE1 and TLE3 in cancer.
• To explore the functional impact of a specific phosphorylation site on TLE protein activity.
• To determine if TLE protein activity can be modulated to affect cancer cell response to chemotherapy.

Main Methods:

• Analysis of TLE1 and TLE3 gene expression in various cancers using The Cancer Genome Atlas (TCGA) database.
• In vitro experiments involving retroviral transduction of TLE1 and TLE3 into A549 lung cancer cells.
• Site-directed mutagenesis to alter the amino-terminal phosphorylation site in TLE1 and TLE3.
• Validation of findings in an adipocyte differentiation system.

Main Results:

• Significant differences in TLE1 and TLE3 expression were observed across multiple cancer types.
• Introduction of TLE3 into lung cancer cells enhanced paclitaxel efficacy, whereas TLE1 introduction reduced it.
• Modulating the conserved amino-terminal phosphorylation site interconverted the activities of TLE1 and TLE3.
• These phosphorylation-dependent functional differences were also observed in adipocyte differentiation.

Conclusions:

• A single amino-terminal phosphorylation site critically distinguishes the oncogenic or tumor-suppressive functions of highly homologous TLE proteins.
• This phosphorylation site dictates differential activities of TLE1 and TLE3, impacting cancer cell chemosensitivity.
• Targeting this phosphorylation site could offer novel therapeutic strategies for cancer treatment.